What You Should Know:
– Clarapath, a leading medical robotics company raises $36M in its Series B-1 round led by Northwell Ventures with participation from strategic players like Mayo Clinic and Ochsner Ventures, bringing Clarapath’s total funding to $75M.
– The company is on a mission to modernize and transform pathology labs through automation and robotics.
The Pathology Challenge: Backlog, Labor Shortages, and Manual Processes
Pathology, the microscopic examination of tissues, forms the backbone of disease diagnosis and treatment across various conditions like cancer, autoimmune diseases, and more. In the US alone, over 12 million biopsies are performed annually, creating a substantial workload for pathology labs. Unfortunately, these labs face a multi-pronged crisis:
- Severe Labor Shortages: Qualified pathologists are in high demand, leading to delays and backlogs in diagnoses.
- Rising Caseloads: The increasing number of biopsies creates additional strain on already stretched resources.
- Outdated Processes: Tissue sample preparation remains a manual and time-consuming process.
Clarapath’s Solution: SectionStar™ and Robotics for Efficient Pathology
Clarapath aims to become the first US-based company to address these challenges with a groundbreaking approach – healthcare robotics and automation. Their flagship product, SectionStar™, is poised to revolutionize the way pathology labs operate.
Benefits of automation in pathology labs include:
- Reduced Backlogs and Faster Diagnoses: Automation can streamline tissue processing, leading to faster turnaround times and improved patient outcomes.
- Alleviating Labor Shortages: Robotics can take over repetitive tasks, freeing up pathologists’ time for more complex cases.
- Standardized Workflows: Automation helps to ensure consistent and reliable tissue preparation, minimizing human error.
Investing in the Future
The new funding will fuel Clarapath’s efforts in several key areas:
- Commercializing SectionStar™: This innovative system automates the sectioning and transfer of tissue samples, significantly improving lab efficiency and consistency.
- Expanding Sales and Service: Clarapath will extend its reach to equip more labs with its advanced robotic solutions.
- Enhancing Manufacturing: The company plans to invest in precision manufacturing capabilities to ensure consistent production of its robotic systems.
- Driving Innovation: Continued research and development will bring forth even more advanced tools to further transform the field of pathology.
